ipilimumab
bms
['melanoma']
median overall survival time was longer with tils (25.8 months versus 18.9 months; hr 0.83; 95% ci 0.54 1.27), but did not reach statistical significance (p=0.39) #tils #immunotherapy #celltherapy #cellulartherapeutics #cancer #melanoma #tilrx #esmo22 #esmo2022 #myesmo
#Medicine| Dir. & Host @MedNewsWeek| Research #Oncology #COVID19 #Immunotherapy #celltherapy #tcellrx #CART #bmtsm| About Me: https://t.co/PZG3UGoJrh